immatics launches Phase I/II study of IMA910 cancer vaccine in colorectal cancer
Second proof-of-concept study by cancer immunotherapy specialist
immatics biotechnologies GmbH announced the start of a Phase I/II trial of its IMA910 cancer vaccine in patients with advanced colorectal cancer. IMA910 is a peptide-based therapeutic vaccine that consists of more than a dozen synthetic tumor-associated peptides (TUMAPs) representing different tumor antigens specific for colorectal cancer. The vaccine is developed to slow or halt tumor progression in cancer patients.
Aim of the study is to assess the preliminary safety and first evidence of efficacy of the vaccine. The study will enroll about 70 patients in 8 European countries. immatics received the approval for the study by the first four competent authorities in Belgium, United Kingdom, Hungary and Germany. The first patient will be treated within the next few weeks.
"With IMA910 we have moved our second drug candidate into proof-of-concept studies", adds Dr Harpreet Singh, Chief Scientific Officer of immatics. "Our approach is unique: it is based on immunogenic peptides derived from real tumor cells and addresses not just one antigen but a broad spectrum. We therefore think that our drug candidates can provide a significant improvement in the treatment of cancer."
Other news from the department research and development
